研究显示黑人成人接受阿尔茨海默病抗淀粉样蛋白药物的几率低86%,西班牙裔成人低79%
Who gets Alzheimer's drugs? Race, vulnerability and health status shape access
密歇根大学团队在 Neurology 发表的研究显示,与非西班牙裔白人相比,黑人成人接受抗淀粉样蛋白药物的几率低86%,西班牙裔成人低79%。研究从逾100万轻度认知障碍或痴呆成人数据库中识别出2427名接受抗淀粉样蛋白药物治疗的患者,并与相似的未治疗人群比较,发现收入、教育、住房与社区资源等社会经济条件较差者获得治疗的可能性接近减半。
研究基于百万人级数据库比较不同种族与健康状态人群的用药机会,为理解新药可及性差异提供观察性证据。
The first disease-modifying drugs for Alzheimer's disease offer patients the ability to slow cognitive decline by targeting amyloid plaques in the brain. But a new study suggests that not all patients have the same opportunity to receive these treatments.
Research led by Michigan Medicine found that Black adults had 86% lower odds, and Hispanic adults had 79% lower odds of receiving anti-amyloid medication compared to non-Hispanic white adults.
The findings, published in Neurology, highlight potential disparities in access to a new class of Alzheimer's treatments as use of these therapies increases.
"The association we found between race/ethnicity and anti-amyloid medication use raises important questions about how patients are identified, evaluated and ultimately selected for treatment," said Melissa Elafros, co-first author and Andrea and Lawrence A. Wolfe Research Professor at the University of Michigan Medical School.
"It's critical that we understand and address the disparities we are seeing today so that as many patients as possible receive benefits."
From a database of over 1 million adults with mild cognitive impairment or dementia, the research team identified 2,427 patients who received anti-amyloid medication and compared them to a similar group of untreated patients.
They found that race, ethnicity and health comorbidities were strongly associated with whether patients received treatment.
Participants who faced greater social and economic disadvantages, as measured by factors including income, education and access to housing and neighborhood resources, were nearly half as likely to receive the latest treatments.
Once treatment began, patients were equally likely to take anti-amyloid medications as prescribed, regardless of race or ethnicity.
"Although race, ethnicity and overall vulnerability are associated with whether patients receive anti-amyloid medication, we found no differences in initial adherence among those who start treatment," said Brian C. Callaghan, senior author and Eva L. Feldman, MD, Ph.D. Professor at U-M Medical School.
"This suggests that interventions should focus on helping eligible patients start therapy, rather than on adherence after treatment begins."
Publication details
Association between demographics and social drivers of health with anti-amyloid medication utilization and initial adherence among people with dementia and mild cognitive impairment, Neurology (2026). DOI: 10.1212/WNL.0000000000218594
Journal information: Neurology
Key medical concepts
Clinical categories
Who's behind this story?
Sadie Harley
BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →
Robert Egan
Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →
Citation: Who gets Alzheimer's drugs? Race, vulnerability and health status shape access (2026, October 15) retrieved 15 October 2026 from https://medicalxpress.com/news/2026-10-alzheimer-drugs-vulnerability-health-status.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
来源:Medical Xpress · medicalxpress.com